Tags

Type your tag names separated by a space and hit enter

Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease.
Immunol Lett. 2015 Nov; 168(1):80-8.IL

Abstract

INTRODUCTION

There is a great need to identify readily accessible, blood-based biomarkers for Parkinson's disease (PD) that are useful for accurate early detection and diagnosis. This advancement would allow early patient treatment and enrollment into clinical trials, both of which would greatly facilitate the development of new therapies for PD.

METHODS

Sera from a total of 398 subjects, including 103 early-stage PD subjects derived from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study, were screened with human protein microarrays containing 9,486 potential antigen targets to identify autoantibodies potentially useful as biomarkers for PD. A panel of selected autoantibodies with a higher prevalence in early-stage PD was identified and tested using Random Forest for its ability to distinguish early-stage PD subjects from controls and from individuals with other neurodegenerative and non-neurodegenerative diseases.

RESULTS

Results demonstrate that a panel of selected, blood-borne autoantibody biomarkers can distinguish early-stage PD subjects (90% confidence in diagnosis) from age- and sex-matched controls with an overall accuracy of 87.9%, a sensitivity of 94.1% and specificity of 85.5%. These biomarkers were also capable of differentiating patients with early-stage PD from those with more advanced (mild-moderate) PD with an overall accuracy of 97.5%, and could distinguish subjects with early-stage PD from those with other neurological (e.g., Alzheimer's disease and multiple sclerosis) and non-neurological (e.g., breast cancer) diseases.

CONCLUSION

These results demonstrate, for the first time, that a panel of selected autoantibodies may prove to be useful as effective blood-based biomarkers for the diagnosis of early-stage PD.

Authors+Show Affiliations

Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Durin Technologies, Inc., New Brunswick, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA.Department of Mathematics, Rowan University, Glassboro, NJ, USA.Durin Technologies, Inc., New Brunswick, NJ, USA.Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA; Durin Technologies, Inc., New Brunswick, NJ, USA. Electronic address: nagelero@rowan.edu.No affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26386375

Citation

DeMarshall, Cassandra A., et al. "Potential Utility of Autoantibodies as Blood-based Biomarkers for Early Detection and Diagnosis of Parkinson's Disease." Immunology Letters, vol. 168, no. 1, 2015, pp. 80-8.
DeMarshall CA, Han M, Nagele EP, et al. Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease. Immunol Lett. 2015;168(1):80-8.
DeMarshall, C. A., Han, M., Nagele, E. P., Sarkar, A., Acharya, N. K., Godsey, G., Goldwaser, E. L., Kosciuk, M., Thayasivam, U., Belinka, B., & Nagele, R. G. (2015). Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease. Immunology Letters, 168(1), 80-8. https://doi.org/10.1016/j.imlet.2015.09.010
DeMarshall CA, et al. Potential Utility of Autoantibodies as Blood-based Biomarkers for Early Detection and Diagnosis of Parkinson's Disease. Immunol Lett. 2015;168(1):80-8. PubMed PMID: 26386375.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential utility of autoantibodies as blood-based biomarkers for early detection and diagnosis of Parkinson's disease. AU - DeMarshall,Cassandra A, AU - Han,Min, AU - Nagele,Eric P, AU - Sarkar,Abhirup, AU - Acharya,Nimish K, AU - Godsey,George, AU - Goldwaser,Eric L, AU - Kosciuk,Mary, AU - Thayasivam,Umashanger, AU - Belinka,Benjamin, AU - Nagele,Robert G, AU - ,, Y1 - 2015/09/16/ PY - 2015/06/11/received PY - 2015/09/14/revised PY - 2015/09/14/accepted PY - 2015/9/20/entrez PY - 2015/9/20/pubmed PY - 2016/9/14/medline KW - Autoantibodies KW - Biomarkers KW - Diagnosis KW - Parkinson’s disease KW - Protein microarrays SP - 80 EP - 8 JF - Immunology letters JO - Immunol Lett VL - 168 IS - 1 N2 - INTRODUCTION: There is a great need to identify readily accessible, blood-based biomarkers for Parkinson's disease (PD) that are useful for accurate early detection and diagnosis. This advancement would allow early patient treatment and enrollment into clinical trials, both of which would greatly facilitate the development of new therapies for PD. METHODS: Sera from a total of 398 subjects, including 103 early-stage PD subjects derived from the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study, were screened with human protein microarrays containing 9,486 potential antigen targets to identify autoantibodies potentially useful as biomarkers for PD. A panel of selected autoantibodies with a higher prevalence in early-stage PD was identified and tested using Random Forest for its ability to distinguish early-stage PD subjects from controls and from individuals with other neurodegenerative and non-neurodegenerative diseases. RESULTS: Results demonstrate that a panel of selected, blood-borne autoantibody biomarkers can distinguish early-stage PD subjects (90% confidence in diagnosis) from age- and sex-matched controls with an overall accuracy of 87.9%, a sensitivity of 94.1% and specificity of 85.5%. These biomarkers were also capable of differentiating patients with early-stage PD from those with more advanced (mild-moderate) PD with an overall accuracy of 97.5%, and could distinguish subjects with early-stage PD from those with other neurological (e.g., Alzheimer's disease and multiple sclerosis) and non-neurological (e.g., breast cancer) diseases. CONCLUSION: These results demonstrate, for the first time, that a panel of selected autoantibodies may prove to be useful as effective blood-based biomarkers for the diagnosis of early-stage PD. SN - 1879-0542 UR - https://www.unboundmedicine.com/medline/citation/26386375/Potential_utility_of_autoantibodies_as_blood_based_biomarkers_for_early_detection_and_diagnosis_of_Parkinson's_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-2478(15)30034-1 DB - PRIME DP - Unbound Medicine ER -